Case Report

Brain Parenchyma (pons) Involvement by Visceral Leishmaniasis: A Case Report

*Moslem SEDAGHATTALAB¹, Arsalan AZIZI²

1. Dept. of Internal Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
2. Dept. of Pathology, Yasuj University of Medical Sciences, Yasuj, Iran

Abstract
Leishmaniasis, as a vector-borne disease, is transmitted by sandfly and caused by *Leishmania* protozoa. Brain involvement rarely occurs in visceral leishmaniasis. In this paper, a rare case of pons involvement by visceral leishmaniasis (VL) is reported. A 54 yr old man from Southwest of Iran (Yasuj) presented to the Emergency Ward with a 3-wk history of headache (continuous, throbbing, and general), fever, chills, weakness, anorexia, and weight loss.

Introduction

Leishmaniasis is a vector-borne disease, transmitted by sandfly and caused by *Leishmania* protozoa. This parasite affects the human’s reticuloendothelial system. A wide range of syndromes is produced by Leishmania species, including visceral leishmaniasis (VL), mucosal leishmaniasis, and cutaneous leishmaniasis (1).

In Iran, *L. infantum* is the main etiological agent of human VL and *L. tropica* is the second cause of VL. The incidence of visceral and cutaneous leishmaniasis is 0.092 and 22 per 100000 population, respectively. Kala-azar is endemic in southern and northwestern areas of Iran but VL also has been reported sporadically in other parts of country. The main reservoir hosts for *L. infantum* are domestic dogs and wild canines in various parts of country (2-4).

Neurologic involvement occurs rarely in visceral leishmaniasis (5). In this paper, a man with visceral leishmaniasis is described, with
headache and fever, and imaging revealed involvement of brain in pons area.

**Case presentation**

A 54 yr old man from Southwest of Iran (Yasuj) presented to the Emergency Ward with a 3-wk history of headache (continuous, throbbing, and general), fever, chills, weakness, anorexia, and weight loss. He also had a history of benign prostatic hyperplasia, gastroesophageal reflux disease, and hemorrhoid. Medications were tamsulosin, propranolol, rabeprazole, and cathartic syrup. His parents had no any congenital or infectious diseases.

On examination, the body temperature and blood pressure were 38 °C and 130/82 mm Hg, respectively. Abdominal examination revealed mild tenderness in right upper quadrant and moderate splenomegaly. All other examinations were normal.

The hemoglobin was 8.1 (gr/dl), the white blood cell count 1900, retic count 0.5%, and the platelet count 20000. The ESR was 56 (mm/h), alanine aminotransferase 84 (Iu/l), aspartate aminotransferase 67 (Iu/l), alkaline phosphatase 401 ( Iu/l), albumin 3.4 (gr/dl) , conjugated bilirubin 0.6 (mg/dl), ferritin 658.6 (mcg/dl), serum iron 23 (mcg/dl), total iron binding capacity (TIBC) 116 (mcg/dl). Other laboratory tests such as creatinine, blood sugar, partial thromboplastin time, prothrombin time, urinalysis, stool exam, sputum exam, wright test, 2ME, calcium, phosphorus, magnesium, and prostate-specific antigen were normal.

Serologic tests for HBV, HCV, and HIV were negative.

Abdominal ultrasonography revealed mild hepatomegaly and moderate splenomegaly. Doppler ultrasound of abdomen showed dilation of splenic veins such as superior mesenteric vein (15 mm) and portal vein (15 mm).

A computerized tomography (CT) scan of brain revealed no abnormal finding. Axial fluid-attenuated inversion recovery MRI image (FLAIR) revealed an increase in signal intensity of central part of right side of pons (Fig. 1). Bone marrow aspiration and biopsy revealed macrophages with numerous *Leishmania* amastigotes (Fig. 2). Treatment with amphotericin B was initiated and the patient symptoms resolved completely. In second bone marrow exam, no amastigote was observed.

Five months after initial presentation and treatment with amphotericin B our patient has no any neurological morbidity and disability.

![Fig. 1: MRI image (FLAIR) revealed an increase in signal intensity of pons](http://ijpa.tums.ac.ir)
Discussion

Visceral leishmaniasis (known as Kala-azar) is reported in Middle East countries, Pakistan, India, Sudan, Ethiopia, Kenya, Uganda, Somalia, Mediterranean Europe, Mexico, Argentina, and Brazil. Clinical manifestations of visceral leishmaniasis include fever, chills, weight loss, weakness, splenomegaly, and hepatomegaly. Serum levels of liver aminotransferases and immunoglobulins are raised, also they have anemia, thrombocytopenia, and leukopenia (1). In Iran, the main symptoms and signs in patients with Kala-azar included paleness, fever, splenomegaly, hepatomegaly, and lymphadenopathy (2).

In leishmaniasis, involvement of peripheral nervous system is more common than central nervous system (6). Peripheral nervous system involvement was reported as burning feet, foot drop, hearing loss, and multiple cranial nerve palsies (7). Schwann cells may act as a target for Leishmania (8).

We described a rare case of pons involvement by visceral leishmaniasis. Although involvement of brain parenchyma in visceral leishmaniasis is rare and mechanism of central and peripheral nervous system involvement by leishmaniasis is poorly understood, but haematogenous dissemination was described as mechanism of central nervous system involvement by visceral leishmaniasis (9).

Conclusion

Leishmaniasis should be considered in differential diagnosis of patients who presented with fever, headache, and central nervous system lesions.

Acknowledgements

We would like to thank Dr. Zafar Masoumi for his cooperation in this study.

Conflicts of interest

The authors declare no conflicts of interest.

References

1. Shyam Sundar. leishmaniasis. In: Harrison's Principles of Internal Medicine. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J, eds., 19th edition, New York, Mc Graw Hill, 2015: 1387.
Sedaghattalab & Azizi: Brain Parenchyma (pons) Involvement by Visceral …

2. Mohebali M. Visceral leishmaniasis in Iran: Review of the Epidemiological and Clinical Features. Iran J Parasitol. 2013; 8(3):348-58.
3. Heydarpour F, Sari AA, Mohebali M et al. Incidence and Disability-Adjusted Life Years (DALYS) Attributable to Leishmaniasis in Iran, 2013. Ethiop J Health Sci. 2016; 26(4):381-8.
4. Mohebali M, Edrissian GH, Nadim A et al. Application of direct agglutination test (DAT) for the diagnosis and seroepidemiological studies of visceral leishmaniasis in Iran. Iran J Parasitol. 2006; 1:15-25.
5. Diniz LM, Duani H, Freitas CR et al. Neurological involvement in visceral leishmaniasis: case report. Rev Soc Bras Med Trop. 2010;43(6):743-5.

6. Maia CS, Monteiro MC, Gavioli EC et al. Neurological disease in human and canine leishmaniasis–clinical features and immunopathogenesis. Parasite Immunol. 2015;37(8):385-93.
7. Hashim FA, Ahmed AE, el Hassan M et al. Neurologic changes in visceral leishmaniasis. Am J Trop Med Hyg. 1995; 52(2):149-54.
8. Baetas-da-Cruz W, Corte-Real S, Cavalcante LA. Schwann cells as putative safe host cells for Leishmania amazonensis. Int J Infect Dis. 2009;13(5):e323-4.
9. Llanos-Cuentas A, Valencia BM, Petersen CA. Neurological manifestations of human leishmaniasis. Handb Clin Neurol. 2013; 114:193-8.

Available at: http://ijpa.tums.ac.ir 148